Biotechnology

Beam Therapeutics

Beam Therapeutics Presents BEAM-302 Phase 1/2 Data, Plans Accelerated Approval in 2026

Beam Therapeutics released FY2026 Q1 earnings on May 7, 2026 (EST), with actual revenue of USD 31.74 M (forecast USD 12.22 M) and actual EPS of USD -0.9133 (forecast USD -1.0121)

John M. Evans sold Beam Therapeutics stock

Beam Therapeutics Announces Mid-Term Results of Sickle Cell Treatment Drug Trial and Plans to Submit BLA Application

Beam Therapeutics released FY2025 annual earnings on February 24 Pre-Market (EST), actual revenue USD 139.74 M (forecast USD 38.5 M), actual EPS USD -0.8099 (forecast USD -4.3126)

Beam Therapeutics released FY2025 Q4 earnings on February 24 Pre-Market (EST), actual revenue USD 114.11 M (forecast USD 12.95 M), actual EPS USD 2.327 (forecast USD -1.1299)

Beam Therapeutics Inc. Announces 2025 Fiscal Year Financial Report

Beam Therapeutics Reports Financials, Launches New Project, and Closes Financing Deal

H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics with a Target Price of $80

Beam Therapeutics Makes Progress in Gene Drug Projects and Reaches Consensus with FDA

Beam Therapeutics Reports $1.25 Billion in Cash and Cash Equivalents for Q4 2025

ARK Invest Makes Major Bets on Gene Editing and Genomics

Evercore ISI Maintains Buy Rating for Beam Therapeutics

Wedbush Maintains Buy Rating on Beam Therapeutics

JonesTrading analyst maintains buy rating for Beam Therapeutics with positive clinical data for sickle cell disease treatment

Beam Therapeutics Announces Significant Efficacy in Sickle Cell Disease Clinical Trial

Capital Fund Management and other institutional investors increase holdings in Beam Therapeutics

Evercore ISI Gives Beam Therapeutics 'Outperform' Rating

JonesTrading analyst maintains Buy rating for Beam Therapeutics

Beam Therapeutics released FY2025 Q3 earnings on November 4 (EST), actual revenue USD 9.698 M (forecast USD 12.72 M), actual EPS USD -1.0999 (forecast USD -1.0143)

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

BEAM

Beam Therapeutics is advancing its base-editing platform for hematology and liver disease, with a potential biologics license application for its sickle cell disease candidate expected by year-end. CEO John Evans highlighted progress in the alpha-1 antitrypsin deficiency program, confirming a 60-milligram dose as effective. The company is aligned with the FDA for an accelerated approval path for BEAM-302, planning to enroll 50 patients for further studies.

Market Beat

ROYAL BANK OF CANADA

Beam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program Advances

LABU

SBIO

Beam Therapeutics (BEAM) is presenting updated biomarker data from its BEACON trial, but its share price has recently declined by 13.58%. Despite a 56.12% return over the past year, it trades below the analyst target of $51.07. A risk-adjusted valuation suggests a fair value of $150, indicating it is undervalued. However, future growth depends on clinical outcomes and regulatory decisions. Investors are encouraged to explore other undervalued stocks for better opportunities.

Simplywall

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

iShares Biotechnology ETF

VanEck Biotech ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

A Look At Beam Therapeutics (BEAM) Valuation As New BEACON Trial Data And Partnerships Draw Attention

IBBQ

Citi analyst Samantha Semenkow has reaffirmed a Buy rating for Beam Therapeutics (BEAM) stock, maintaining a $68 price target. The positive outlook is based on the company's strong clinical momentum, including progress towards a pivotal cohort for BEAM-302 and a planned BLA filing for risto-cel by 2026. Recent data supports Beam's efficacy and advantages in treatment outcomes. Bernstein also assigned a Buy rating with a $39 price target, further supporting the positive sentiment around the stock.

- Citigroup analyst Samantha Semenkow maintains a bullish rating on BEAM stock, giving it a buy recommendation.  
- The positive outlook stems from Beam Therapeutics' strong clinical and regulatory momentum, particularly with the BEAM-302 trial and upcoming submissions for risto-cel.  
- Bernstein also rated the stock as a buy, with a target price of $39.00, reinforcing confidence in the company's growth potential.

Tip Ranks

Invesco Nasdaq Biotechnology ETF

Citigroup

AllianceBernstein

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Beam Therapeutics: Buy Rating Reaffirmed as Clinical Momentum Builds and $68 Price Target Remains Unchanged

Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1 | BEAM Stock News

StockTitan

Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1 | BEAM Stock News

BEEM

IBA has launched AdaPTinsight XR, an advanced CBCT imaging solution for proton therapy, enhancing image-guided patient positioning and treatment. This state-of-the-art technology aims to improve precision in cancer treatment, offering effective therapy with minimal side effects. The integration of this imaging solution within the Proteus® Portfolio reflects a commitment to better patient outcomes, marking a significant milestone in cancer treatment advancements.

Unusual Whales

Beamr Imaging

Beam Global

IBA introduces AdaPTinsight XR, the next generation of CBCT imaging for image-guided proton therapy

In Q1 2026, Beam Therapeutics reported a net loss of $94.32 million but a significant revenue increase to $31.74 million, driven by collaboration milestones. The company advanced its base-editing pipeline with positive data for BEAM-302 and risto-cel, and secured $1.20 billion in cash along with a $100 million credit facility. The potential BLA submission for risto-cel and BEAM-302's accelerated approval path are key catalysts. Analysts project a revenue of $123.9 million and earnings of $15.8 million by 2029, with a fair value estimate of $51.20, indicating a 63% upside from the current price.

Will Beam Therapeutics' (BEAM) Revenue Surge, Pipeline Updates and Added Liquidity Change Its Narrative?

Earnings Watch

Beam Therapeutics | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 31.74 M

Beam Therapeutics (BEAM) has gained attention after being recognized by TIME as one of the 10 Most Influential Health & Life Science Companies for 2026, alongside positive BEACON trial results for sickle cell disease. The stock has seen a 13.24% return over the past week and 26.75% over the past month. Currently valued at approximately $3.0 billion, analysts suggest a fair value of $150.00 per share, indicating significant growth potential. However, the stock's P/S ratio of 22x raises concerns about its pricing relative to industry averages. Investors should weigh the optimistic outlook against potential risks in Beam's pipeline.

A Look At Beam Therapeutics (BEAM) Valuation After TIME Recognition And BEACON Trial Progress

Beam Therapeutics(BEAM.US)

Beam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program Advances

A Look At Beam Therapeutics (BEAM) Valuation As New BEACON Trial Data And Partnerships Draw Attention

Beam Therapeutics: Buy Rating Reaffirmed as Clinical Momentum Builds and $68 Price Target Remains Unchanged

Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1 | BEAM Stock News

IBA introduces AdaPTinsight XR, the next generation of CBCT imaging for image-guided proton therapy

Will Beam Therapeutics' (BEAM) Revenue Surge, Pipeline Updates and Added Liquidity Change Its Narrative?

Beam Therapeutics | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 31.74 M

A Look At Beam Therapeutics (BEAM) Valuation After TIME Recognition And BEACON Trial Progress